Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]MK-9470 is a selective, high-affinity inverse agonist (human IC50, 0.7 nM) for the cannabinoid CB1 receptor (CB1R) developed for use in human brain imaging. It's a positron emission tomography (PET) radiotracer that allows for non-invasive visualization and quantification of CB1 receptor expression in vivo. The tracer shows high specific binding in brain regions known to express CB1 receptors, including the cerebral cortex, cerebellum, caudate/putamen, globus pallidus, substantia nigra, and hippocampus. It's primarily used as a research tool for studying CB1 receptor biology and pharmacology in neuropsychiatric disorders and for evaluating target engagement in clinical trials of CB1 receptor inverse agonists.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]MK-9470.